- Explore the latest clinical guideline updates on pharmacological treatments and personalised pain management strategies
- Find out what the most promising emerging therapies are for OA pain control
- Listen to experts discuss unmet patient needs in OA pain control
- Discover the latest congress updates on pain management in OA
Osteoarthritis (OA) is the most prevalent chronic joint disease and a prominent cause of pain, distress and disability1. The burden of OA to patients is often underestimated2 and the health economic burden is growing with increased life expectancy and increased prevalence of other risk factors, such as obesity and additional comorbidities1. Current pharmacological treatments for OA are focused on symptomatic analgesia. Guideline changes have downgraded the use of paracetamol and opioids and highlighted the need for personalised pain management3–5. There are, however, emerging therapies for OA pain control which could impact the burden of OA in the future1.
Find out what our medical experts recommend to get the most benefit from existing treatments and what the impact of new therapies could be. Also look out for our patient ‘Marie’ who has knee osteoarthritis. Find out about how OA affects her life and the different treatments that she has been prescribed in the past to control her pain, and then answer a series of interactive questions designed to test your knowledge.
Start a conversation with your colleagues on clinical recommendations from 2021 and 2020 osteoarthritis (OA) congresses.
Why are there still unmet needs for pain management in patients with osteoarthritis (OA) Medthority hosted a virtual roundtable in June 2020 with three medical experts to address these needs and provide clear guidance for physicians.
Burden of OA associated pain
Discover the burden of OA pain for patients and the economy.
A personalised pain management strategy is required
Do you know which assessment tools which are best for OA?
Clinical guidelines for treating OA-associated pain have recently been updated
Do you know the latest guideline updates for treating OA pain?
Find out what is currently under investigation for OA pain.
- Alcaraz MJ, Guillén MI, Ferrándiz ML. Emerging therapeutic agents in osteoarthritis. Biochemical Pharmacology. 2019;165:4–16.
- Castrejon I, Shakoor N, Chua JR, Block JA. Discordance of global assessment by patients and physicians is higher in osteoarthritis than in rheumatoid arthritis: a cross-sectional study from routine care. Rheumatol Int. 2018;38(11):2137–2145.
- Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578–1589.
- Bruyere O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350.
- Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220–233.
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.